These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1818 related articles for article (PubMed ID: 21969500)

  • 1. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
    J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
    Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
    J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
    J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
    Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
    Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Zhu CQ; da Cunha Santos G; Ding K; Sakurada A; Cutz JC; Liu N; Zhang T; Marrano P; Whitehead M; Squire JA; Kamel-Reid S; Seymour L; Shepherd FA; Tsao MS;
    J Clin Oncol; 2008 Sep; 26(26):4268-75. PubMed ID: 18626007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
    Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
    J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
    Miller VA; Riely GJ; Zakowski MF; Li AR; Patel JD; Heelan RT; Kris MG; Sandler AB; Carbone DP; Tsao A; Herbst RS; Heller G; Ladanyi M; Pao W; Johnson DH
    J Clin Oncol; 2008 Mar; 26(9):1472-8. PubMed ID: 18349398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
    Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
    Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
    J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
    Hirsch FR; Varella-Garcia M; Bunn PA; Franklin WA; Dziadziuszko R; Thatcher N; Chang A; Parikh P; Pereira JR; Ciuleanu T; von Pawel J; Watkins C; Flannery A; Ellison G; Donald E; Knight L; Parums D; Botwood N; Holloway B
    J Clin Oncol; 2006 Nov; 24(31):5034-42. PubMed ID: 17075123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer.
    Mok T; Ladrera G; Srimuninnimit V; Sriuranpong V; Yu CJ; Thongprasert S; Sandoval-Tan J; Lee JS; Fuerte F; Shames DS; Klughammer B; Truman M; Perez-Moreno P; Wu YL
    Lung Cancer; 2016 Aug; 98():1-8. PubMed ID: 27393499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
    Garassino MC; Martelli O; Broggini M; Farina G; Veronese S; Rulli E; Bianchi F; Bettini A; Longo F; Moscetti L; Tomirotti M; Marabese M; Ganzinelli M; Lauricella C; Labianca R; Floriani I; Giaccone G; Torri V; Scanni A; Marsoni S;
    Lancet Oncol; 2013 Sep; 14(10):981-8. PubMed ID: 23883922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
    O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R
    Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Massarelli E; Varella-Garcia M; Tang X; Xavier AC; Ozburn NC; Liu DD; Bekele BN; Herbst RS; Wistuba II
    Clin Cancer Res; 2007 May; 13(10):2890-6. PubMed ID: 17504988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study.
    Mazières J; Brugger W; Cappuzzo F; Middel P; Frosch A; Bara I; Klingelschmitt G; Klughammer B
    Lung Cancer; 2013 Nov; 82(2):231-7. PubMed ID: 23972450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.
    Ichihara S; Toyooka S; Fujiwara Y; Hotta K; Shigematsu H; Tokumo M; Soh J; Asano H; Ichimura K; Aoe K; Aoe M; Kiura K; Shimizu K; Date H; Shimizu N
    Int J Cancer; 2007 Mar; 120(6):1239-47. PubMed ID: 17192902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
    Fiala O; Pesek M; Finek J; Krejci J; Ricar J; Bortlicek Z; Benesova L; Minarik M
    Neoplasma; 2013; 60(1):26-32. PubMed ID: 23067213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 91.